Effect of hANP for prevention of atrial fibrillation after CABG: a randomised controlled trial

Effect of hANP for prevention of atrial fibrillation after CABG: a randomised controlled trial - NU-HIT trial for prevention of Af

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003958

Enrollment

700

Registered

2010-07-28

Start date

2001-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myocardial infarction, angina

Interventions

Perioperative administration of hANP Perioperative non-administration of hANP

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient undergoing isolated CABG patients from whom informed consent was obtained

Exclusion criteria

Exclusion criteria: past of arrhythmia sinus bradycardia at rest (<50/min) second -or third-degree AV block clinical hypothyroidism or hyperthyroidism Doctor's decision not to register to this regimen

Design outcomes

Secondary

Measure	Time frame
ANP, renin, anigotensin-II, aldsterone 1)Age 2)renin, anigotensin-II, aldsterone 3)ANP, BNP, cyclic GMP 4)CK-MB, H-FABP 5)CRP 6)mortality, complication	—

Primary

Measure	Time frame
Incidence of postoperative atrial fibrillation	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026